Skip to main content
Top
Published in: Breast Cancer Research and Treatment 1/2018

01-07-2018 | Letter to the Editor

What to look for in cell-free DNA from breast cancer patients

Authors: Giuseppe Bronte, Sara Ravaioli, Sara Bravaccini

Published in: Breast Cancer Research and Treatment | Issue 1/2018

Login to get access

Excerpt

In a recent paper by Cheng J et al., published in Breast Cancer Research and Treatment, the authors resume the debate about the usefulness of liquid biopsy in breast cancer (BC) patients. They found an independent prognostic role of cell-free DNA (cfDNA) integrity in repetitive DNA elements (ALU and LINE1) detected by quantitative PCR in metastatic BC patients. They also observed a reduction in cfDNA concentration and an increase in cfDNA integrity from baseline to the first cycle of systemic therapy [1]. This analysis was based on the hypothesis that, as malignant cells undergo necrosis and processes other than apoptosis, circulating tumor DNA is consequently expected to be composed of longer fragments. …
Literature
Metadata
Title
What to look for in cell-free DNA from breast cancer patients
Authors
Giuseppe Bronte
Sara Ravaioli
Sara Bravaccini
Publication date
01-07-2018
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2018
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-018-4728-8

Other articles of this Issue 1/2018

Breast Cancer Research and Treatment 1/2018 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine